This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Sign In
Don’t have an account?
    Ophthalmology Events & On Demand Webinars
    Ophthalmology Learning Zone
    Ophthalmology Podcasts
    Ophthalmology Resources
  • Ophthalmology
  • Oncology
  • Oncology Events & On Demand Webinars
    Oncology Learning Zone
  • Therapy Areas
  • Oncology Podcasts
    Oncology Resources
  • Cardiology
  • Cardiology Events & On Demand Webinars
    Cardiology Learning Zone
    Cardiology Podcasts
    Cardiology Resources
  • Women's Health
  • Women's Health Events & On Demand Webinars
    Women's Health Learning Zone
    Women's Health Podcasts
    Women's Health Resources
    Service Optimisation & Formularies
    Risk Minimisation Materials
Bayer cross
BAYER FOR PROFESSIONALSYour Resource Portal
Ophthalmology Events & On Demand Webinars
Ophthalmology Learning Zone
Ophthalmology Podcasts
Ophthalmology Resources
  • EYLEA® (aflibercept) 8 mg
  • EYLEA® (aflibercept) 2 mg
  • Nubeqa® (darolutamide)
  • Xofigo®▼ (radium-223 dichloride)
Oncology Events & On Demand Webinars
Oncology Learning Zone
  • Ophthalmology
  • Oncology
  • Cardiology
  • Women's Health
Oncology Podcasts
Oncology Resources
  • Beyonttra®▼ (acoramidis)
  • Kerendia®▼ (finerenone)
  • Xarelto® (rivaroxaban)
Cardiology Events & On Demand Webinars
Cardiology Learning Zone
Cardiology Podcasts
Cardiology Resources
  • Angeliq® (1mg estradiol hemihydrate and 2mg drospirenone)
  • Jaydess®▼ (13.5mg levonorgestrel)
  • Kyleena® (19.5mg levonorgestrel)
  • Mirena® [Br][/Br] (52mg levonorgestrel)
  • Qlaira® (estradiol valerate/dienogest)
Women's Health Events & On Demand Webinars
Women's Health Learning Zone
Women's Health Podcasts
Women's Health Resources
Service Optimisation & Formularies
Risk Minimisation Materials
closesearch
Recent Searches
    You are now leaving BayerPro

    The contents and the policies on the website you are visiting is not controlled by the BayerPRO team.
    Do you wish to continue?

    Homepage Banner

    Latest resources

    View more
    Real World Experience
    Practical insights into the experiences of clinicians implementing treatment with EYLEA® (aflibercept) 8 mg in the UK
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3143, April 2026
    Suspecting ATTR-CM
    Beyonttra®▼ (acoramidis) | Resources to support recognition of the 'red flags'
    Beyonttra Prescribing Information
    PP-BEY-GB-0243, April 2026
    Ophthalmology Patient Support Materials
    Access our range of downloadable patient support booklets and other resources
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3117, March 2026
    Ophthalmology Resources
    Access useful, downloadable ophthalmology resources
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3081, March 2026

    Events & webinars

    View more
    BNMS 2024
    Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)
    Xofigo Prescribing Information
    NUBEQA Prescribing Information
    PP-XOF-GB-0598, January 2025
    ATTR-CM & Carpal Tunnel Syndrome
    Beyonttra®▼ (acoramidis) | Early diagnosis of ATTR-CM using carpal tunnel biopsies
    Beyonttra Prescribing Information
    PP-BEY-GB-0226, March 2026
    CV Summit 2025 - Highlights
    Register Your Interest for 2026 Here
    Beyonttra Prescribing Information
    PP-BEY-GB-0007, November 2025
    Cultural Inequalities In Contraception Services
    Hear from Dr Radhika Vohra on how best to support your patients requiring contraception
    Kyleena® Prescribing Information
    Mirena® Prescribing Information
    PP-PF-WHC-IUS-GB-0113, March 2025

    Learning Zone

    View more
    Request An Interactive Pharmacist’s Guide
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2388, May 2025
    NUBEQA® (darolutamide) Drug-Drug Interactions Learning Guide
    NUBEQA Prescribing Information
    PP-NUB-GB-2129, March 2025
    Urogenital Symptoms and Sexual Difficulties
    (5 mins) Often underreported and undertreated symptoms that significantly affect a woman's relationships.
    Mirena® Prescribing Information
    PP-PF-WHC-IUS-GB-0085 October 2024
    Musculoskeletal Symptoms, Anxiety, Low Mood and Brain Fog
    (4 mins) Causes for musculoskeletal (MSK) symptoms, how menopause can worsen existing anxiety and depression.
    Mirena® Prescribing Information
    PP-PF-WHC-IUS-GB-0084 October 2024

    Podcasts

    View more
    Conversations at ESMO 2025
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2752, March 2026
    Conversations at ESMO 2025
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2751, March 2026
    ESMO 2025
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2700, October 2025
    The Macular Minute: Podcast Series
    Your source for quick expert insights in medical retina
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3090, March 2026

    Products

    View more
    Angeliq® (1mg estradiol hemihydrate and 2mg drospirenone)
    Introduction to Angeliq
    Angeliq Prescribing Information
    PP-ANG-GB-0012, March 2026
    NUBEQA® (darolutamide)
    About NUBEQA
    NUBEQA Prescribing Information
    PP-NUB-GB-2950, March 2026
    Beyonttra®▼ (acoramidis) - Overview
    About Beyonttra
    Beyonttra (acoramidis) Prescribing Information
    PP-BEY-GB-0213, March 2026
    EYLEA® (aflibercept) 2 mg
    Discover data and resources about EYLEA 2 mg
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-2793, March 2025

    Register with BayerPRO

    To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.

     

    Don’t have an account?